Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer

NCT00992186 is registered in ClinicalTrials.gov with Centocor Research & Development, Inc. as lead sponsor.

NCT NCT00992186
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992186 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter, Phase 2 Study of Single-Agent CNTO 888 (an Anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects With Metastatic Castrate-Resistant Prostate Cancer
Lead sponsor
Centocor Research & Development, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
July 31, 2011
Enrollment
46 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer